HK
IBRX icon

Horizon Kinetics’s ImmunityBio IBRX Stock Holding History

Horizon Kinetics’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$300K Buy
258,475
+119,476
+86% +$273K 0.01% 386
2018
Q3 		$514K Buy
138,999
+4,499
+3% +$14.2K 0.01% 262
2018
Q2 		$412K Buy
134,500
+39,016
+41% +$144K 0.01% 315
2018
Q1 		$371K Buy
95,484
+16,272
+21% +$71.3K 0.01% 407
2017
Q4 		$356K Buy
79,212
+9,514
+14% +$45.1K 0.01% 418
2017
Q3 		$382K Buy
+69,698
New +$430K 0.01% 405

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Horizon Kinetics's IBRX Position: Q4 2018 in Review

Horizon Kinetics increased its ImmunityBio (IBRX) stake by 86% in Q4 2018, buying an estimated $273K and bringing the position to 258,475 shares worth $300K. The position accounts for 0.01% of the portfolio, ranked #386.

Horizon Kinetics first reported a position in IBRX in Q3 2017 and has held it in 6 quarters since. The position peaked at $514K in Q3 2018. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2018.

  • Horizon Kinetics held 258,475 shares of ImmunityBio worth $300K as of Q4 2018.
  • Horizon Kinetics bought 119,476 ImmunityBio shares in Q4 2018, an estimated $273K.
  • ImmunityBio made up 0.01% of Horizon Kinetics's portfolio in Q4 2018, its #386 holding.
  • Horizon Kinetics first reported a position in ImmunityBio in Q3 2017 and has held it in 6 quarters since.
  • Horizon Kinetics's ImmunityBio position peaked at $514K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2018.

Based on Horizon Kinetics's 13F filing for Q4 2018, filed 14 Feb 2019.